Cooper Companies Inc Stock (COO) Moved Down by 14.08% on Sep 10: What Investors Need To Know

Cooper Companies Inc (COO) moved down by 14.08%. The Healthcare Services & Equipment sector is down by 0.69%. The company underperformed the industry. Top 3 stocks by turnover in the sector: Unitedhealth Group Inc (UNH) down 0.58%; Boston Scientific Corp (BSX) down 3.96%; Thermo Fisher Scientific Inc (TMO) down 0.59%.

What is driving Cooper Companies Inc (COO)’s stock price down today?

The Cooper Companies experienced a severe selloff following its fiscal third-quarter earnings report, where top-line revenue missed Wall Street consensus expectations despite a modest beat on adjusted earnings per share. The primary driver of the revenue shortfall was proactive U.S. channel inventory destocking within the core CooperVision contact lens unit, which stagnated organic sales growth. More critically, management lowered its fiscal fourth-quarter and full-year revenue and earnings per share outlook, noting that inventory rationalization will continue to weigh on performance in the near term. This revision marks the fourth guidance cut in roughly two years, exacerbating concerns over operational execution and underlying momentum in the vision-care franchise.

Investor sentiment was further dampened by the conclusion of the company's months-long strategic review regarding CooperSurgical. The board of directors unanimously decided to retain the women's healthcare and fertility business rather than proceed with a divestiture or strategic transaction. Management highlighted that potential acquisition proposals were negatively impacted by valuation disconnects associated with a new competitor entering the non-hormonal intrauterine device market and recent litigation expenses. Because many market participants had anticipated a sale that could unlock shareholder value or yield transaction proceeds, the decision to maintain the current corporate structure led to widespread disappointment.

The combination of top-line headwinds, reduced forward guidance, and strategic uncertainty triggered a wave of negative analyst actions. Multiple major investment firms downgraded the equity rating to neutral stances while sharply reducing their price targets. Analysts pointed to challenging margin leverage heading into the next fiscal year and expressed skepticism regarding a rapid recovery in channel demand. Although management announced an expanded share repurchase authorization to support long-term capital allocation, the immediate market reaction reflects heightened risk aversion as institutional investors reevaluate the company's growth trajectory and margin profile.

Technical Analysis of Cooper Companies Inc (COO)

Technically, Cooper Companies Inc (COO) shows a MACD (12,26,9) value of -3.393, indicating a sell signal. The RSI at 14.995 suggests oversold condition and the Williams %R at 85.723 suggests oversold condition. Please monitor closely.

Media Coverage of Cooper Companies Inc (COO)

In terms of media coverage, Cooper Companies Inc (COO) shows a coverage score of 55, indicating a moderate level of media attention. The overall market sentiment index is currently in bearish zone.

Fundamental Analysis of Cooper Companies Inc (COO)

Cooper Companies Inc (COO) is in the Healthcare Services & Equipment industry. Its latest annual revenue is $4.09B, ranking 29 in the industry. The net profit is $374.90M, ranking 33 in the industry. Company Profile

Over the past month, multiple analysts have rated the company as Buy, with an average price target of $83.19, a high of $92.00, and a low of $66.00.

More details about Cooper Companies Inc (COO)

Company Specific Risks:

• Drastic Guidance Reduction and Top-Line Miss: The company reported Q3 FY2026 revenue of $1.066 billion, missing consensus estimates of $1.10 billion, while lowering full-year adjusted EPS guidance to $4.51–$4.55 and Q4 EPS guidance to $1.05–$1.09 (well below the $1.20 analyst consensus), marking its fourth outlook reduction in two years.
• Persistent Channel Inventory Destocking in CooperVision: Management cited aggressive U.S. channel inventory reductions in its core contact-lens unit as a primary driver for flat segment sales and a 2% organic decline in the Americas, warning that destocking will continue to suppress revenue into the fourth quarter.
• Failed CooperSurgical Divestiture and Wall Street Downgrades: The Board concluded its strategic review by retaining CooperSurgical after receiving subpar acquisition proposals influenced by upcoming non-hormonal IUD competition and litigation liabilities, frustrating investors and triggering analyst downgrades, including a rating reduction to Market Perform by William Blair.
• One-Off Tax Benefit Masking Operational Margin Pressure: Reported GAAP EPS of $2.24 was heavily skewed by a non-recurring $307.2 million U.K. tax examination settlement, masking a 60-basis-point year-over-year gross margin compression to 66.7% and rising Q4 cost pressures from elevated commercial spending and foreign currency headwinds.